(Q37682882)

22 August 2017

1 reference

title

Trastuzumab: A review of its use as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (English)

1 reference

Erb-b2 receptor tyrosine kinase 2

22 August 2017

1 reference

1 reference

1 reference

1

Karly P Garnock-Jones

1 reference

22 August 2017

3

Lesley J Scott

1 reference

22 August 2017

2

Gillian M Keating

1 reference

22 August 2017

1 January 2010

1 reference

22 August 2017

1 reference

22 August 2017

70

1 reference

22 August 2017

2

1 reference

22 August 2017

215-239

1 reference

https://scigraph.springernature.com/pub.10.2165/11203700-000000000-00000

22 August 2017

0 references

cites work

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells

1 reference

12 December 2020

1 reference

12 December 2020

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

1 reference

12 December 2020

Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.

1 reference

12 December 2020

Adjuvant trastuzumab: progress, controversies, and the steps ahead

1 reference

12 December 2020

Pharmacokinetics, Safety, and Efficacy of Trastuzumab Administered Every Three Weeks in Combination With Paclitaxel

1 reference

12 December 2020

Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone

1 reference

12 December 2020

Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring

1 reference

12 December 2020

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

1 reference

12 December 2020

Antitumor activity of combinations of anti-HER-2 antibody trastuzumab and oral fluoropyrimidines capecitabine/5'-dFUrd in human breast cancer models

1 reference

12 December 2020

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

12 December 2020

Trastuzumab : in HER2 and hormone receptor co-positive metastatic breast cancer

1 reference

12 December 2020

Radiosensitization of chemotherapy-refractory, locally advanced or locally recurrent breast cancer with trastuzumab: a phase II trial

1 reference

12 December 2020

Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer

1 reference

12 December 2020

Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer

1 reference

12 December 2020

Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line.

1 reference

12 December 2020

Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized

1 reference

12 December 2020

P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells.

1 reference

12 December 2020

Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2.

1 reference

12 December 2020

Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells

1 reference

12 December 2020

MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells

1 reference

12 December 2020

Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action

1 reference

12 December 2020

Trastuzumab in early stage breast cancer: a cost-effectiveness analysis for Belgium

1 reference

12 December 2020

Trastuzumab plus tamoxifen: anti-proliferative and molecular interactions in breast carcinoma.

1 reference

12 December 2020

ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency

1 reference

12 December 2020

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

12 December 2020

Rac1 contributes to trastuzumab resistance of breast cancer cells: Rac1 as a potential therapeutic target for the treatment of trastuzumab-resistant breast cancer

1 reference

12 December 2020

TGFalpha expression impairs Trastuzumab-induced HER2 downregulation

1 reference

12 December 2020

Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells

1 reference

12 December 2020

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

1 reference

12 December 2020

Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278).

1 reference

12 December 2020

Trastuzumab--mechanism of action and use in clinical practice

1 reference

12 December 2020

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 reference

12 December 2020

Synergistic interactions between tamoxifen and trastuzumab (Herceptin).

1 reference

12 December 2020

Phase II feasibility and pharmacokinetic study of concurrent administration of trastuzumab and high-dose chemotherapy in advanced HER2+ breast cancer

1 reference

12 December 2020

A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer

1 reference

12 December 2020

Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Bre

1 reference

12 December 2020

Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule.

1 reference

12 December 2020

Tumour biology: herceptin acts as an anti-angiogenic cocktail.

1 reference

12 December 2020

Trastuzumab: a pharmacoeconomic review of its use in early breast cancer

1 reference

12 December 2020

Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.

1 reference

12 December 2020

Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer.

1 reference

12 December 2020

The costs of treating breast cancer in the US: a synthesis of published evidence

1 reference

12 December 2020

Pharmacokinetics of gemcitabine combined with trastuzumab in patients with advanced breast cancer

1 reference

12 December 2020

Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial

1 reference

12 December 2020

Sensitization of breast cancer cells to radiation by trastuzumab

1 reference

12 December 2020

Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling

1 reference

12 December 2020

Trastuzumab: a review of its use in the management of HER2-positive metastatic and early-stage breast cancer

1 reference

12 December 2020

Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial

1 reference

12 December 2020

Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells

1 reference

12 December 2020

Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2

1 reference

12 December 2020

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

1 reference

12 December 2020

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

12 December 2020

Neoadjuvant trastuzumab induces apoptosis in primary breast cancers

1 reference

12 December 2020

Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells

1 reference

12 December 2020

Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a model-based analysis of the HERA and FinHer trial

1 reference

12 December 2020

Influence of trastuzumab on epirubicin pharmacokinetics in metastatic breast cancer patients

1 reference

12 December 2020

Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial

1 reference

12 December 2020

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

1 reference

12 December 2020

Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial

1 reference

12 December 2020

Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival

1 reference

12 December 2020

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study

1 reference

12 December 2020

Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial

1 reference

12 December 2020

10.2165/11203700-000000000-00000

Identifiers

DOI

1 reference

PubMed ID

20108993

Dimensions Publication ID

22 August 2017

0 references

1 reference

PubMed ID

20108993